{"id":444,"date":"2015-03-27T10:39:00","date_gmt":"2015-03-27T10:39:00","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=444"},"modified":"2025-05-05T18:03:32","modified_gmt":"2025-05-05T12:33:32","slug":"what-are-your-views-on-gene-therapy","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy","title":{"rendered":"What are your views on Gene Therapy?"},"content":{"rendered":"
\n

“We used to think that our fate was in our stars, but now we know that, in large measure, our fate is in our genes<\/strong>, “quotes James Watson.<\/p>\n<\/blockquote>\n

This fate that Watson is talking about is contained in our genes, and deals with a new technique, GENE THERAPY<\/strong>.<\/p>\n

\"gdfg\"Gene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises to help diseased tissues and organs work properly. This approach is different from traditional drug-based approaches, which may treat symptoms but not the underlying genetic problems.<\/p>\n

The treatment sounds magical, but the complexity of designing and delivering arises. The safety issues slowed the progress, following events like death of Jess Gelsinger, who died in 1999 just weeks after receiving an experimental gene therapy in a clinical trial being conducted by the University of Pennsylvania.<\/p>\n

Although gene therapy is a promising treatment option for a number of diseases, the technique remains risky and is still under study to make sure that it will be safe and effective.<\/p>\n

Also some genetic disorders are rare in nature affecting 1 in million. For such patients, Gene therapy can be a miracle but high cost of developing a treatment can make it unappealing for the pharmaceutical companies. With a limited number of patients to recover those expenses from, developers may never earn money from treating such rare genetic disorders. And some patients may never be able to afford them.<\/p>\n

The first milestone in gene therapy, Gendicine<\/strong>, developed by Shenzhen SiBiono GeneTech was approved in China in 2003 for the treatment of head and neck cancers and the biggest watershed moment was Glybera<\/strong>, a gene therapy for lipoprotein lipase deficiency, launched in Germany at a price of more than 1 million euros ($1.1 million).<\/p>\n

Meanwhile, companies like bluebird bio<\/strong> and Spark Therapeutics<\/strong> generated impressive clinical data with programmes of their own.<\/p>\n

The success has generated renewed interest from both private and public equity investors as well as pharmaceutical companies, such as Bayer<\/strong> and Sanofi,<\/strong> which have willingly provided much-needed resources to companies working in the field in the form of financing and partnerships, helping to drive what could turn out to be a virtuous circle of success.<\/p>\n

DelveInsight Gene Therapy Reports<\/strong><\/p>\n

DelveInsight\u2019s Reports<\/strong> have already established a reputation of offering the affordable and comprehensive industry coverage and \u201con-the-ground\u201d analysis in virtually every region of the world. These reports provide complete information for over 300 gene therapies which are in the pipeline for various therapy areas like; Oncology, Genitourinary, Dermatology, Central nervous system, Genetic Disorders, Hematological disorders, Metabolic disorders, Ophthalmology, Cardiovascular disease, Respiratory , Immunology, <\/em>and many more\u2026<\/p>\n

DelveInsight\u2019s Gene Therapy Reports<\/strong> cover the entire gene therapy market scenario including technology assessments, licensing opportunities, collaborations, market trends, pipeline coverage and competitive landscape. The report essentially provides DelveInsight\u2019s proprietary market and pipeline analytics which identifies the front runners of all therapeutic areas. It also identifies the potential market movers and future regulatory landscape. These reports are designed to provide the clients with the means to out produce their competitors by developing a product that makes history.<\/p>\n

For more info on Gene Therapy Reports for various Therapeutic areas contact us at: info@delveinsight.com<\/a><\/strong>.<\/p>\n

By Rashi Aggarwal, Associate Analyst, DelveInsight<\/p>\n

Please give your views on Gene Therapy and lets discuss about its potential in the market.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

“We used to think that our fate was in our stars, but now we know that, in large measure, our fate is in our genes, “quotes James Watson. This fate that Watson is talking about is contained in our genes, and deals with a new technique, GENE THERAPY. Gene therapy is an innovative way to […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[107,122,124,180,204,209,256,257,261,278,533,543,568],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-444","post","type-post","status-publish","format-standard","hentry","category-articles","tag-bayer","tag-blockbuster-drugs","tag-bluebird-bio","tag-competitive-landscape","tag-delveinsight","tag-delveinsights-gene-therapy-reports","tag-gendicine","tag-gene-therapies","tag-generic-companies","tag-glybera","tag-sanofi","tag-spark-therapeutics","tag-therapeutic-gene","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"\nWhat are your views on Gene Therapy? - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Gene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"What are your views on Gene Therapy? - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Gene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-27T10:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-05T12:33:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/gdfg.png?w=300\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"What are your views on Gene Therapy? - DelveInsight Business Research","description":"Gene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy","og_locale":"en_US","og_type":"article","og_title":"What are your views on Gene Therapy? - DelveInsight Business Research","og_description":"Gene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises","og_url":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2015-03-27T10:39:00+00:00","article_modified_time":"2025-05-05T12:33:32+00:00","og_image":[{"url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/gdfg.png?w=300","type":"","width":"","height":""}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy","url":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy","name":"What are your views on Gene Therapy? - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy#primaryimage"},"thumbnailUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/gdfg.png?w=300","datePublished":"2015-03-27T10:39:00+00:00","dateModified":"2025-05-05T12:33:32+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gene therapy is an innovative way to fix genetic problem from the source. By adding a corrected copy of a defective gene, gene therapy promises","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/what-are-your-views-on-gene-therapy#primaryimage","url":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/gdfg.png?w=300","contentUrl":"https:\/\/delveinsightblog.files.wordpress.com\/2015\/03\/gdfg.png?w=300"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Blockbuster drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Bluebird bio<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight's Gene Therapy Reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gendicine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Generic Companies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Glybera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Spark therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Therapeutic gene<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Blockbuster drugs<\/span>","<span class=\"advgb-post-tax-term\">Bluebird bio<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight's Gene Therapy Reports<\/span>","<span class=\"advgb-post-tax-term\">Gendicine<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">Generic Companies<\/span>","<span class=\"advgb-post-tax-term\">Glybera<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Spark therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Therapeutic gene<\/span>"]}},"comment_count":"1","relative_dates":{"created":"Posted 11 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Mar 27, 2015","modified":"Updated on May 5, 2025"},"absolute_dates_time":{"created":"Posted on Mar 27, 2015 10:39 am","modified":"Updated on May 5, 2025 6:03 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=444"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/444\/revisions"}],"predecessor-version":[{"id":31682,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/444\/revisions\/31682"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=444"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=444"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}